# Nuclide record nct06894511 (trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/trials/nct06894511/>
  a schema:MedicalTrial ;
  nuclide:kind "trial" ;
  schema:identifier "nct06894511", "NCT06894511" ;
  schema:name "An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC"@en ;
  schema:alternateName "PSMAndARPI"@en ;
  schema:description "A phase 2 trial of FAP-2286, Lutetium-177 vipivotide tetraxetan in prostate cancer, run by Novartis Pharmaceuticals, active and no longer recruiting."@en ;
  schema:url <https://nuclide.cc/trials/nct06894511/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06894511> ;
  nuclide:status "active" ;
  nuclide:tag "ctgov-ingest" ;
  nuclide:phase "2" ;
  nuclide:related <https://nuclide.cc/isotopes/lu-177/> ;
  nuclide:indications <https://nuclide.cc/indications/prostate/>, <https://nuclide.cc/indications/prostate-mcrpc/> ;
  nuclide:drugs <https://nuclide.cc/drugs/fap-2286/>, <https://nuclide.cc/drugs/pluvicto/> ;
  nuclide:companies <https://nuclide.cc/companies/novartis/> .